Targets › NTCP
1 program from 1 company in 4 trials: 2 Phase 3, 2 Phase 2; Infectious disease; next expected readout Jun 2027.
As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins. It is strictly dependent on the extracellular presence of sodium. (UniProt, Q14973)
Open in Phaseline: the race on NTCP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals | Brelovitug (BJT-778) NTCP (sodium taurocholate cotransporting polypeptide) inhibitor | NTCP | Phase 3 | Chronic Hepatitis D Infection; Chronic Hepatitis D | Jun 2027 |
Chronic Hepatitis D Infection (3) Chronic Hepatitis D (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.